Table 2.
N died | 100 day survival | 2 year survival | ||
---|---|---|---|---|
Survival | 14 | 71% (53–89%) | 40% (21–59%) | |
N events | 100 day LFS | 2 year PFS | ||
Leukemia-Free Survival | 14 | 75% (53–88%) | 40% (21–59%) | |
100 day Relapse | 2 year Relapse | |||
Relapse/Progression | 6 | 8% (0–19%) | 26% (8–44%) | |
100 day NRM | 1 year NRM | |||
Non-Relapse Mortality | 8 | 17% (3–31%) | 34% (15–53%) | |
Grade II–IV acute GVHD | 8 | 34% (14–54%) | ||
Maximum grade acute GVHD | N (%) | |||
Grade | None | 14 (58%) | ||
I | 2 (8%) | |||
II | 5 (21%) | |||
III | 2 (8%) | |||
IV | 1 (4%) | |||
1 year chronic GVHD | ||||
Chronic GVHD | 4 | 20% (2–38%) |
Shown are the number (%) and Kaplan Meier (survival, LFS) or cumulative incidence (Relapse, GVHD, NRM) estimates of post-HCT events (± 95% confidence intervals).